Gold Nanocomplex Strongly Modulates the PI3K/Akt Pathway and Other Pathways in MCF-7 Breast Cancer Cell Line

Area of Science:

• Nanomedicine
• Cancer Therapeutics
• Molecular Biology

Background:

• Conjugating drugs with gold nanoparticles (GNP) is a promising strategy in cancer therapy.
• The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is crucial in tumor progression, regulating apoptosis, proliferation, and DNA damage.

Purpose of the Study:

• To investigate the inhibition of the PI3K/Akt pathway and other signaling pathways in MCF-7 cells using gold nanorods (GNR) conjugated with a PI3K inhibitor.
• To evaluate the effects of the drug-GNR nanocomplex on gene and protein expression compared to the free drug or GNR alone.

Main Methods:

• Conjugation of a PI3K inhibitor drug with gold nanorods (GNR).
• Treatment of MCF-7 cell lines with the drug-GNR nanocomplex, free drug, or GNR alone.
• Analysis of gene and protein expression levels, focusing on PI3Kα, transcription factors, apoptotic pathways, cell cycle regulators, and immune response proteins.

Main Results:

• The GNR-drug conjugate significantly modulated PI3Kα expression at both gene and protein levels compared to individual components.
• The nanocomplex treatment substantially altered the gene expression of transcription factors involved in cell growth, proliferation, apoptosis, and cell cycle arrest.
• Significant modifications in the gene expression of regulatory proteins associated with cancer progression and immune responses were observed with the nanocomplex.

Conclusions:

• Drug-conjugated gold nanorods represent a potent strategy for modulating key cancer-related pathways.
• The developed nanocomplex shows significant potential in inhibiting cancer cell growth, inducing apoptosis, and influencing immune responses.
• This approach offers a promising platform for developing targeted cancer therapies with enhanced efficacy.